Precision Biosciences (DTIL) Payables (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Payables of $944000.0 for Q1 2026, up 2.16% year-over-year from $924000.0 in Q1 2025, and up 218.92% quarter-over-quarter from $296000.0 in Q4 2025.
Precision Biosciences (DTIL) Payables (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Payables for 9 consecutive years, with $944000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables rose 2.16% year-over-year to $944000.0; the TTM figure through Mar 2026 stood at $944000.0 (up 2.16% YoY), while the FY2025 annual figure was $296000.0, down 77.44% from the prior year.
- Payables improved to $944000.0 in Q1 2026 per DTIL's latest filing, from $296000.0 in the prior quarter.
- Across five years, Payables topped out at $3.0 million in Q4 2023 and bottomed at $296000.0 in Q4 2025.
- Historically, Payables has averaged $1.0 million across 5 years, with a median of $944000.0 in 2026.
- Annual changes were most pronounced in 2023 — Payables soared 354.52% — and 2025, when it plunged 77.44%.
- Precision Biosciences' Payables stood at $653000.0 in 2022, then surged by 354.52% to $3.0 million in 2023, then sank by 55.8% to $1.3 million in 2024, then slumped by 77.44% to $296000.0 in 2025, then soared by 218.92% to $944000.0 in 2026.
- Business Quant data shows DTIL's Payables at $944000.0 in Q1 2026, $296000.0 in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - | 35.57 Mn |
| 10 | Precision Biosciences | 224.82 Mn | 137.27 Mn | - | 828,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 828,000.00 |
| Mar 31, 2026 | 944,000.00 |
| Dec 31, 2025 | 296,000.00 |
| Sep 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | 1.12 Mn |
| Mar 31, 2025 | 924,000.00 |
| Dec 31, 2024 | 1.31 Mn |
| Sep 30, 2024 | 958,000.00 |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 1.14 Mn |
| Dec 31, 2023 | 2.97 Mn |
| Sep 30, 2023 | 531,000.00 |
| Jun 30, 2023 | 781,000.00 |
| Mar 31, 2023 | 701,000.00 |
| Dec 31, 2022 | 653,000.00 |
| Sep 30, 2022 | 1.06 Mn |
| Jun 30, 2022 | 797,000.00 |
| Mar 31, 2022 | 699,000.00 |
| Dec 31, 2021 | 1.14 Mn |
| Sep 30, 2021 | 486,000.00 |